5 completed, 2 terminated, 1 active not recruiting, 1 recruiting. 5 Phase 1, 3 Phase 2, 1 Phase 3.
By phase and status
Follow tilsotolimod: new trials by email Literature Review of tilsotolimod trials Research Report on tilsotolimod
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
Intratumoral Tilsotolimod, a TLR-9 Agonist, Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced Cancers Ipilimumab, Nivolumab, Tilsotolimod - Advanced Cancer | Phase 1 | Terminated | 25 | 2020-04-10 | 2024-10-18 |
A Randomized Controlled Phase II Trial With Intradermal IMO-2125 in Pathological Tumor Stage (p) T3-4 cN0M0 Melanoma Tilsotolimod, Saline (0.9% sodium chloride) - Malignant Melanoma | Phase 2 | Recruiting | 214 | 2020-01-22 | 2021-04-15 |
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma ABBV-368, Tilsotolimod, Nab-paclitaxel - Advanced Solid Tumors Cancer | Phase 1 | Completed | 30 | 2020-01-22 | 2023-02-27 |
Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206) Tilsotolimod, Nivolumab, Ipilimumab - Solid Tumor | Phase 2 | Active not recruiting | 30 | 2019-10-29 | 2022-02-17 |
A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma Ipilimumab, Tilsotolimod with Ipilimumab - Metastatic Melanoma | Phase 3 | Terminated | 481 | 2018-05-30 | 2022-11-08 |
A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors IMO-2125 - Refractory Solid Tumors, Melanoma | Phase 1 | Completed | 54 | 2017-06-09 | 2020-02-11 |
A Phase 2 Study to Assess the Safety and Efficacy of IMO-2125 With 8 mg Ipilimumab in Patients With Metastatic Melanoma IMO-2125, Ipilimumab - Metastatic Melanoma | Phase 2 | Completed | 53 | 2015-12-01 | 2022-08-03 |
Study of Combination Treatment With IMO-2125 and Ribavirin in Naïve Hepatitis C-infected, Genotype 1 Patients IMO-2125, Saline - Hepatitis C, Treatment Naïve, Genotype 1 Patients | Phase 1 | Completed | 63 | 2009-09-01 | 2019-02-15 |
Placebo-controlled, Dose-escalation Study of the Safety of IMO-2125 (Immunomodulatory Oligonucleotide) in Hepatitis C-infected Patients IMO-2125, Saline placebo - Hepatitis C | Phase 1 | Completed | 58 | 2007-09-01 | 2019-02-15 |
Conditions studied
Melanoma (4) · Hepatitis C (2) · Carcinoma, Squamous Cell (1) · Diabetes Mellitus, Insulin-Dependent, 12 (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Skin Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1)
Sponsors
Idera Pharmaceuticals, Inc. (6) · A.J.M. van den Eertwegh (1) · AbbVie (1) · Gustave Roussy, Cancer Campus, Grand Paris (1)
Countries
United States (6) · France (4) · Netherlands (3) · Germany (2) · Israel (2) · Spain (2) · Australia (1) · Canada (1) · Czechia (1) · Italy (1) · Puerto Rico (1) · Sweden (1) · United Kingdom (1)
Top investigators
Alice Bexon, MD (1) · Tanja de Gruijl (1)
Results publications
PMID 40048691, PMID 41956545
NIH funding
2018 (1), 2019 (1)